Dear Reader,
We would like to welcome you to the first issue of the 20th volume of Expert Opinion on Investigational Drugs (EOID). Hopefully, we have served our authors and readers well over the last 20 years.
EOID is listed on MEDLINE (and several other indices) and enjoyed an increase in impact factor last year to 4.218. This impact factor places the journal among the top 10% of all those listed (© Thompson Reuters, Journal Citation Reports® 2010). In 2008, we introduced Original Research papers to EOID, to provide a wider variety of articles for our readers. We are delighted with the quality of original contributions so far and look forward to expanding this in the future. As of next year, we will also begin to publish Clinical Trial Evaluations, which we hope will work in tandem with our existing Drug Evaluations, providing readers with the latest research and most comprehensive, up-to-the-minute data from key opinion leaders in the field.
Going forward, EOID will continue to cover a broad field across the pre-launch pipeline, focussing on the latest discoveries and development platforms over a range of therapy areas. This is most certainly a challenging time for the field, as indicated by the growing trend for mergers and acquisitions by big pharma, and the general year-on-year decrease in newly approved drugs. The changing landscape of drug development will surely provide new ways of thinking and we look forward to being at the forefront of the field at this pivotal time.
Finally, we are immensely grateful for the voluntary contributions of our authors and referees in continuing the ongoing growth and success of the journal. As always, the Editorial Office welcomes unsolicited articles, and we are also keen to receive Editorials and Correspondence on current controversies and new therapeutic areas from leaders in the field.
We hope that we can continue to be a valuable resource to our readers in the future and look forward to the success of another 20 years.